

Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform. Hutchison's innovation platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases. The company's commercial platform includes the manufacturing, marketing, and distribution of prescription and over-the-counter pharmaceuticals in China as well as certain consumer products in Hong Kong. The vast majority of the company's revenue is generated through its commercial platform. Among its major competitors, Hutchison China Meditech is ranked in 4th place for NPS while GlaxoSmithKline is 1st, and Bristol Myers Squibb is 2nd.